Gyre Therapeutics (GYRE) Cash & Equivalents (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cash & Equivalents of $37.5 million for Q1 2026, up 917.36% year-over-year from $3.7 million in Q1 2025, and up 50.75% quarter-over-quarter from $24.9 million in Q4 2025.
Gyre Therapeutics (GYRE) Cash & Equivalents (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cash & Equivalents for 17 consecutive years, with $37.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 917.36% year-over-year to $37.5 million; the TTM figure through Mar 2026 stood at $37.5 million (up 917.36% YoY), while the FY2025 annual figure was $24.9 million, up 110.81% from the prior year.
- Cash & Equivalents advanced to $37.5 million in Q1 2026 per GYRE's latest filing, from $24.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $75.4 million in Q2 2022 and bottomed at $2.2 million in Q3 2023.
- Historically, Cash & Equivalents has averaged $22.6 million across 5 years, with a median of $16.0 million in 2024.
- Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 90.35% — and 2026, when it soared 917.36%.
- Gyre Therapeutics' Cash & Equivalents stood at $23.1 million in 2022, then tumbled by 54.17% to $10.6 million in 2023, then climbed by 11.51% to $11.8 million in 2024, then soared by 110.81% to $24.9 million in 2025, then soared by 50.75% to $37.5 million in 2026.
- Business Quant data shows GYRE's Cash & Equivalents at $37.5 million in Q1 2026, $24.9 million in Q4 2025, and $40.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 43.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.30 Mn |
| Mar 31, 2026 | 37.50 Mn |
| Dec 31, 2025 | 24.88 Mn |
| Sep 30, 2025 | 40.40 Mn |
| Jun 30, 2025 | 36.50 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 11.80 Mn |
| Sep 30, 2024 | 15.90 Mn |
| Jun 30, 2024 | 16.10 Mn |
| Mar 31, 2024 | 8.68 Mn |
| Dec 31, 2023 | 10.58 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 11.53 Mn |
| Mar 31, 2023 | 8.10 Mn |
| Sep 30, 2022 | 23.09 Mn |
| Jun 30, 2022 | 75.39 Mn |
| Mar 31, 2022 | 34.82 Mn |
| Dec 31, 2021 | 44.35 Mn |
| Sep 30, 2021 | 64.50 Mn |
| Jun 30, 2021 | 86.50 Mn |